What Will Happen to Karyopharm Therapeutics Inc (KPTI) Next? The Stock Just Increased A Lot

September 17, 2017 - By Henry Gaston

Investors sentiment increased to 2.4 in Q4 2016. Its up 0.88, from 1.52 in 2016Q3. It improved, as 5 investors sold Karyopharm Therapeutics Inc shares while 15 reduced holdings. 14 funds opened positions while 34 raised stakes. 24.99 million shares or 9.31% more from 22.86 million shares in 2016Q3 were reported.
Retail Bank Of Montreal Can reported 16,318 shares stake. 20,496 were reported by Nationwide Fund Advsrs. Deutsche State Bank Ag has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Trexquant Invest Limited Partnership owns 29,007 shares. Susquehanna Group Llp has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Blackrock Investment Mngmt Ltd Liability Company reported 103,508 shares. Tiaa Cref Investment Management Ltd Liability reported 70,557 shares. Tudor Investment Et Al holds 11,624 shares or 0% of its portfolio. Schwab Charles Inc invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Proshare Ltd Com, a Maryland-based fund reported 31,601 shares. Citigroup Inc invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Retail Bank Of Mellon, New York-based fund reported 112,287 shares. 6,266 are owned by Barclays Public Ltd Company. The Kansas-based Creative Planning has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Blackrock accumulated 6,994 shares.

The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a huge mover today! The stock increased 4.07% or $0.43 on September 15, reaching $11. About 432,710 shares traded or 146.40% up from the average. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 21.19% since September 17, 2016 and is uptrending. It has outperformed by 4.49% the S&P500.
The move comes after 7 months positive chart setup for the $518.53M company. It was reported on Sep, 17 by Barchart.com. We have $11.99 PT which if reached, will make NASDAQ:KPTI worth $46.67 million more.

Analysts expect Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report $-0.64 EPS on November, 6.They anticipate $0.05 EPS change or 7.25 % from last quarter’s $-0.69 EPS. After having $-0.64 EPS previously, Karyopharm Therapeutics Inc’s analysts see 0.00 % EPS growth.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 22 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, March 15 with “Hold”. Raymond James initiated the stock with “Outperform” rating in Friday, May 27 report. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The rating was maintained by JP Morgan with “Overweight” on Monday, March 14. As per Wednesday, September 9, the company rating was initiated by Jefferies. The stock has “Buy” rating by MLV on Wednesday, August 12. The stock has “Outperform” rating by Leerink Swann on Tuesday, August 11. Bank of America downgraded the shares of KPTI in report on Tuesday, March 15 to “Underperform” rating. The rating was initiated by JP Morgan on Wednesday, September 2 with “Overweight”. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, September 8 report.

More notable recent Karyopharm Therapeutics Inc (NASDAQ:KPTI) news were published by: Seekingalpha.com which released: “Karyopharm Therapeutics’ (KPTI) CEO Michael Kauffman on Q2 2017 Results …” on August 08, 2017, also Streetinsider.com with their article: “Karyopharm Therapeutics (KPTI) Presents Selinexor and KPT-9274 Clinical Data …” published on September 08, 2017, Streetinsider.com published: “Karyopharm Therapeutics (KPTI) Names Michael Falvey as Chief Financial Officer” on September 12, 2017. More interesting news about Karyopharm Therapeutics Inc (NASDAQ:KPTI) were released by: Fool.com and their article: “Why Karyopharm Therapeutics Inc Stock Gained 16.4% in March” published on April 07, 2017 as well as Seekingalpha.com‘s news article titled: “Karyopharm Therapeutics: Buy, Sell, Or Hold?” with publication date: June 30, 2017.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The company has market cap of $518.53 million. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It currently has negative earnings. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export compounds that inhibit the nuclear export protein, XPO1.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.